GENE EDITING SOLUTIONS
Delivering the Next Evolution of Healthcare
Recombinetics is a recognized leader in animal gene editing and associated applied technologies for biomedical research, regenerative medicine and animal agriculture.
We leverage our proprietary gene editing platform to commercialize and deploy technologies through four subsidiaries that pivotally impact human health and longevity and add value to farm animals.
FACING THE FACTS
people are currently on the U.S. transplant list—83% are waiting for a kidney
of all clinical trials fail
smallholders are raising unproductive animals
Groundbreaking Technology for Life-Changing Solutions
Recombinetics has the most experienced and reliable animal gene-editing team on the planet developing solutions through four customer-facing subsidiaries focused on three key areas:
Recombinetics Merges with Makana Therapeutics to Accelerate Transplantation
Makana Therapeutics has become Recombinetics Inc.’s newest subsidiary and is exclusively focused on addressing the organ shortage crisis. Recombinetics and Makana have expertise and strong, synergistic intellectual property positions in clinical organ transplantation, genetic engineering, reproductive technology, and xenotransplantation. The merger allows our scientists to focus on and commercialize a pipeline of transplantable cells, tissues, and organs for human patient use.